Policy

How lax social media policies help fuel a prescription drug boom

Prescription drug ads are all over TikTok, Facebook and Instagram. As the potential harms become clear, why haven’t the companies updated their advertising policies?

Pill capsules with Instagram and Facebook likes and notifications inside

Even as providers like Cerebral draw federal attention, Meta’s and TikTok’s advertising policies still allow telehealth providers to turbocharge their marketing efforts.

Illustration: Overearth/iStock/Getty Images Plus

In the United States, prescription drug advertisements are as commonplace as drive-thru lanes and Pete Davidson relationship updates. We’re told every day — often multiple times a day — to ask our doctor if some new medication is right for us. Saturday Night Live has for decades parodied the breathless parade of side effect warnings tacked onto drug commercials. Here in New York, even our subway swipes are subsidized by advertisements that deliver the good news: We can last longer in bed and keep our hair, if only we turn to the latest VC-backed telehealth service.

The U.S. is almost alone in embracing direct-to-consumer prescription drug advertisements. Nations as disparate as Saudi Arabia, France and China all find common ground in banning such ads. In fact, of all developed nations, only New Zealand joins the U.S. in giving pharmaceutical companies a direct line to consumers.

As it so happens, Americans are also highly medicated. A Mayo Clinic study from 2013 found that nearly 70% of Americans regularly took at least one prescription drug. Nearly half the population took at least two, and more than 20% of Americans took five or more. The researchers identified prescription drug abuse as the “fastest-growing drug problem” in the U.S. They also found prescription rates had increased significantly over that preceding decade.

Given the continuity of these trends, it would be easy to overlook a new factor in the equation: social media. Telehealth services have spent millions of dollars promoting prescription drugs on TikTok, Instagram and Facebook. They play on users' insecurities, describing symptoms as vague as “stress” and “losing track of time.” Mood-altering medications such as SSRIs are sold as having straightforward benefits, with companies promising those suffering from depression and loneliness that 80% of customers feel better with treatment.

One major telehealth provider, Cerebral, is now under investigation by the Department of Justice over possible violations of the Controlled Substances Act. Nurse practitioners working for Cerebral said they felt pressure to see dozens of patients a day and push prescriptions, according to reports from Insider, The Wall Street Journal and Bloomberg. (A Cerebral spokesperson told The Wall Street Journal they encourage clinicians not to rush diagnoses and provide time beyond 30 minutes if needed.)

Even as providers like Cerebral draw federal attention, Meta’s and TikTok’s advertising policies still allow telehealth providers to turbocharge their marketing efforts, enticing many patients to start treatments they may regret. As one Cerebral patient told Protocol, “On principle, I want to shout from the mountaintops so no one else falls into their nonsense.”

Ad policies

Both Meta and TikTok allow telehealth providers to promote prescription drugs to users ages 18 and up in the U.S. and New Zealand. Both companies make a distinction between promoting prescription medication, which is allowed, and direct drug sales, which are not. Meta and TikTok work with third-party compliance companies such as LegitScript to approve telehealth providers. Advertisements must also comply with any other relevant platform rules — for example, both platforms prohibit ads for weight loss treatments.

When asked for comment, spokespeople from Meta and TikTok referred Protocol to their respective advertising and community guidelines. (Meta’s policies are available here and here, and TikTok’s are here, here and here.) After being contacted by Protocol, Meta also removed three advertisements from its sites for violating its policies.

Meta and TikTok also say ads cannot contain misleading or inaccurate claims. However, medical experts said advertisements on their platforms do exactly that. On several prior occasions, the companies pulled certain pharmaceutical ads only after the media brought policy violations to their attention. And despite the high stakes involved in promoting medication, both companies rely in large part on automated ad verification systems, which can be prone to error.

Telehealth provider Done, for example, promoted a TikTok ad that describes how being “spacey, forgetful, or chatty” can be a symptom of ADHD. Another Done ad warned symptoms of ADHD in women “are often viewed as character traits rather than symptoms.” In an active ad campaign on Meta, Done promises gaining access to “worry-free refills” is “as easy as” taking a one-minute assessment, followed by a 30-minute appointment available as soon as the next day. (Many of the ad campaigns referenced in this article come from Meta rather than from TikTok because, to Meta’s credit, it has a transparency tool for archiving ad campaigns.)

Ads that generalize ADHD symptoms could violate Meta’s and TikTok’s own policies on misleading consumers, as nonprofit research organization Media Matters points out.

“I think this is really playing on people’s insecurities,” Dr. Kevin Martin Antshel, a psychology professor at Syracuse University who specializes in ADHD, told Protocol. Dr. Antshel noted that ADHD in adults often co-occurs with other psychological disorders such as anxiety and depression. He expressed concern that ads from telehealth providers were leading people to believe ADHD could be treated with stimulants alone, which he said is almost never the case.

Telehealth providers also seem to play on users’ insecurities when promoting erectile dysfunction medication. On Instagram, a recently removed ad campaign from Hims depicted a man asking himself, “What if it happens again today? What if I can’t get it up?” Another of its ads, which was active as of June 26 but has since been removed, shows a couple in bed with text overlaid: “POV: There’s a gorgeous woman in your bed. But you have ED & can’t get it up.” Some of the videos instruct users to “take the quiz” — a rather casual euphemism for kicking off a process that could lead to a medical diagnosis — next to a picture of someone holding a pill.

Meta has touted Roman, one of the telehealth providers that sells ED medication, as a “success story” that could serve as a case study for marketers. Meta’s case study details how Roman was able to double its sales and click-through rate on an ad campaign that promoted testosterone supplements between mid-September and mid-November 2019. Roman was among the top 10 mobile advertising spenders on Facebook that year, as were Pfizer, Allergan and Merck.

Active ad campaigns from Hims entice customers with simple solutions for treating anxiety and depression. One advertisement — which directs users to a page offering generic versions of SSRIs Prozac and Zoloft — tells viewers that “80% of customers feel better with treatment.”

Such straightforward promises don’t always align with patient experiences. One Cerebral patient described suffering severe withdrawal symptoms after being unable to schedule a refill appointment through the company. “I would fret for days over collecting my meds. I would become sick and incapable when they’d miss the refill,” the person told Protocol.

“I find myself constantly pushing [Cerebral] on people because if they use my reference code I can get a $200-off credit,” another Cerebral patient told Protocol.

A campaign from Cerebral that was active as recently as June 26 told viewers they can “overcome opioid use 100% online.” That ad, which featured a large icon of a prescription container, linked to a landing page that said “reduce cravings with medications like Suboxone.”

“It's not ideal,” Jeffrey Scherrer, an associate professor at Saint Louis University who researches opioid use, told Protocol. “But it's certainly a second option for people who otherwise wouldn't even consider seeking care — because I think it offers a little bit more privacy and reduces, for those in rural areas, the need to drive long distances to reach a provider.”

Not your grandpa’s Cialis ad

It’s hard to imagine we’d ever think of the “good old days” for drug advertising as when gray-haired men were suggestively throwing footballs through tire swings between news segments on the Iraq War — yet here we are.

In the television era, regulators faced a simpler task. To start, there were only so many ad slots to fill, which limited the pool of companies that could reasonably afford to buy air time. (Devoted NFL fans can list the blue-chip advertisers by heart.) Broadcast and cable channels could review what went in their slots, and the FCC could feasibly monitor ads on the hundred-or-so cable channels beamed into American living rooms.

Social media advertisements operate at a scale that would have been unfathomable in the television era. Meta hosted over 10 million advertisers on its platform last year. In the fourth quarter of 2021 alone, TikTok removed 3.2 million ads from its platform due to policy infringements.

Social media platforms also allow for more precise targeting. A 2021 investigation from The Markup found that Meta allowed drug manufacturers to target potential patients granularly based on proxy categories. For example, an advertisement promoting a drug used for inflammatory lung disease was aimed at users interested in cigarettes. Similarly, advertisements promoting antipsychotic medication targeted users interested in therapy. Those categories allowed for targeting even though Meta says ad rankings can’t be informed by medical conditions or psychological states.

Age verification poses another significant problem. Meta and TikTok both only allow prescription drug advertisements to be shown to users above the age of 18. But their age verification systems have loopholes that could still let ads slip through to children.

Some prescription drug campaigns seem tailored for younger audiences. A Done ad that ran on Instagram as recently as June 26, but has since been taken down, depicts a young woman telling her mom and dad, “I think I may have ADHD.” The mom in the skit responds, “You’re probably fine — you’ll always be my baby.” The dad advises, “Why don’t you go to the gym and sweat it out.” But the skit concludes with the young woman deciding to ignore her parents and instead take a one-minute assessment from Done.

The other open and troubling question is whether social media worsens users’ mental health, which could make these advertisements more appealing. In leaked internal documents from Facebook, researchers wrote that “teens blame Instagram for increases in the rate of anxiety and depression.” Mark Zuckerberg told Congress those research findings were inconclusive.

“If [social media users] are displaying symptoms of pain, despair, depression, hardship [and] loneliness, then what sort of adverts would you expect to be targeted in those situations?” Professor Victoria Nash, director of the Oxford Internet Institute, asked Protocol. “I wouldn’t be surprised that in a more unregulated context — which I think the U.S. probably is — that this is where you would see prescription drugs being targeted.”

High-frequency digital activities — like scrolling through social media — are so out of sync with the pace of ordinary life that people come to feel more distractible when they aren’t online, according to Antshel. He said social media is “in a sense conditioning people to want this kind of rapid operational speed, constant mental stimulation.” When that stimulation isn’t available in a domain such as the classroom, people are more likely to notice their distractibility, he explained.

Still, Antshel wasn’t ready to call for a ban on prescription drug advertising. He pointed to benefits from drug ads, including reaching people who lack information and access to treatments. “So knowing what to talk about with the primary care physician, I think, could potentially be a good thing. But I can also tell you that I routinely see patients coming in [and] telling me what type of medication they want [and] what type of dose they want.” The issue, he said, is that “we're taking the direct-to-consumer advertising to an extent where it really is creating the potential for harm.”

Climate

How GM plans to make its ambitious EV goals reality

The automaker's chief sustainability officer is optimistic that GM is well-positioned to rapidly scale up the EV side of its business.

"I think everything that’s been put in place to support the transition will be a real positive for the industry and for the country."

Photo: Eva Marie Uzcategui/Bloomberg via Getty Images

Automakers are on the cusp of an entirely new era.

The transition to electric vehicles is quickly becoming more than just theoretical: More models are coming onto the scene every day. This week, the Inflation Reduction Act was signed into law, enshrining a new structure for EV tax credits and offering a boost to domestic critical mineral mining. The transition isn’t coming a moment too soon, given that the transportation sector makes up the largest share of greenhouse gas emissions in the U.S.

Keep Reading Show less
Lisa Martine Jenkins

Lisa Martine Jenkins is a senior reporter at Protocol covering climate. Lisa previously wrote for Morning Consult, Chemical Watch and the Associated Press. Lisa is currently based in Brooklyn, and is originally from the Bay Area. Find her on Twitter ( @l_m_j_) or reach out via email (ljenkins@protocol.com).

As management teams at financial institutions look for best practices to make part of their regular toolkit, they are reaching most for the ones that increase the speed and reduce the risk of large-scale change.

That forward-thinking approach can lead financial institutions to leverage AI technology, which can help give decision-makers trusted tools to solve integral challenges vital to the health of the business. One of the leading providers of AI and machine-learning software, DataRobot continues to attract clients in financial services who want to de-risk their AI investments and rapidly scale AI to almost every part of their operations, resulting in improved productivity and higher customer satisfaction.

Keep Reading Show less
David Silverberg
David Silverberg is a Toronto-based freelance journalist, editor and writing coach. He writes for The Washington Post, BBC News, Business Insider, The Toronto Star, New Scientist, Fodor's, and several alumni magazines. He also writes for brands such as 23andme, Shopify and Bold Commerce. He has served as editor of B2B News Network, Canada's only B2B news magazine, and Digital Journal, a leading pioneer in citizen journalism. Find more about him at www.davidsilverberg.ca
Entertainment

How Embracer Group bought ‘Lord of the Rings’ rights for a bargain

The Swedish holding company, known best for its gaming acquisitions, bought the rights to “The Lord of the Rings.” But the deal is much more complicated than it seems.

Who really owns LOTR's rights?

Photo: New Line/WireImage

A new stakeholder has entered the complex licensing web of “The Lord of the Rings,” and the landmark deal has further complicated the already messy media empire surrounding author J.R.R. Tolkien’s fantasy epic.

The buyer, the acquisition-hungry Swedish gaming conglomerate known as Embracer Group, has purchased Middle-earth Enterprises, and with it the associated film, video game, board game, merchandise, theater production and theme park rights to the core LOTR book trilogy and “The Hobbit'' from its previous owner, The Saul Zaentz Company. Formerly Tolkien Enterprises, Zaentz’s holding group has held onto the rights since purchasing them from United Artists in 1976. (Tolkien initially sold them to UA in 1969, four years before his death.)

Keep Reading Show less
Nick Statt

Nick Statt is Protocol's video game reporter. Prior to joining Protocol, he was news editor at The Verge covering the gaming industry, mobile apps and antitrust out of San Francisco, in addition to managing coverage of Silicon Valley tech giants and startups. He now resides in Rochester, New York, home of the garbage plate and, completely coincidentally, the World Video Game Hall of Fame. He can be reached at nstatt@protocol.com.

Fintech

Upstart has a new plan to sell Wall Street on its loans

The AI-powered lender will hold some loans on its balance sheet as it seeks partners for long-term capital.

Despite the current struggles, Upstart views the marketplace model as the best way to write to keep its loan business growing.

Photo: Upstart

After a revenue drop its CEO called “unacceptable,” the leadership at fintech lender Upstart is making a bet on the strength of its ability to underwrite loans with AI.

The San Mateo company is planning to leave some loans on its balance sheet that investors do not want to buy, as concerns about the economy shift Wall Street away from backing riskier consumer debt. Rather than pull back on its lending in response, the company said it will hold some loans as it seeks longer-term capital partners.

Keep Reading Show less
Ryan Deffenbaugh
Ryan Deffenbaugh is a reporter at Protocol focused on fintech. Before joining Protocol, he reported on New York's technology industry for Crain's New York Business. He is based in New York and can be reached at rdeffenbaugh@protocol.com.
Enterprise

Does your boss sound a little funny? It might be an audio deepfake

Voice deepfake attacks against enterprises, often aimed at tricking corporate employees into transferring money to the attackers, are on the rise. And at least in some cases, they’re succeeding.

Audio deepfakes are a new spin on the impersonation tactics that have long been used in social engineering and phishing attacks, but most people aren’t trained to disbelieve their ears.

Illustration: Christopher T. Fong/Protocol

As a cyberattack investigator, Nick Giacopuzzi’s work now includes responding to growing attacks against businesses that involve deepfaked voices — and has ultimately left him convinced that in today's world, "we need to question everything."

In particular, Giacopuzzi has investigated multiple incidents where an attacker deployed fabricated audio, created with the help of AI, that purported to be an executive or a manager at a company. You can guess how it went: The fake boss asked an employee to urgently transfer funds. And in some cases, it’s worked, he said.

Keep Reading Show less
Kyle Alspach

Kyle Alspach ( @KyleAlspach) is a senior reporter at Protocol, focused on cybersecurity. He has covered the tech industry since 2010 for outlets including VentureBeat, CRN and the Boston Globe. He lives in Portland, Oregon, and can be reached at kalspach@protocol.com.

Latest Stories
Bulletins